Skip to main content
SpringerLink
Log in

Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors

  • Research Articles
  • Drug Actions
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Docetaxel is a P-glycoprotein (P-gp) substrate and metabolized via cytochrome P450 (CYP) 3A subfamily in rats. Morin is an inhibitor of both CYPs and P-gp. Hence, the effects of morin on the intravenous and oral pharmacokinetics of docetaxel were investigated using 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumor rats (DMBA rats) as an animal model of human breast cancer. Docetaxel was administered intravenously (4 mg/kg) and orally (20 mg/kg) without and with morin (15 mg/kg) in DMBA rats. After the intravenous administration of docetaxel in control and DMBA rats with and without morin, the values of non-renal clearance and area under the plasma concentration-time (AUC) for docetaxel were comparable. Morin did not increase AUC or the absolute oral bioavailability (F) for docetaxel after the oral administration of docetaxel in control and DMBA rats with and without morin. The inhibition of hepatic and intestinal metabolism of docetaxel by morin and/or DMBA and the effect of intestinal P-gp inhibition by morin on the pharmacokinetics of docetaxel did not seem to be considerable in DMBA-induced mammary tumor rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baker, S. D., Zhao, M., He, P., Carducci, M. A., Verweij, J., and Sparreboom, A., Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal. Biochem., 324, 276–284 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Ben Reguiga, M., Bonhomme-Faivre, L., and Farinotti, R., Bioavailability and tissue distribution of docetaxel, a Pglycoprotein substrate, are modified by interferon-alpha in rats. J. Pharm. Pharmacol., 59, 401–408 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Bruno, R. and Sanderink, G. J., Pharmacokinetics and metabolism of Taxotere (docetaxel). Cancer Surv., 17, 305–313 (1993).

    PubMed  CAS  Google Scholar 

  • Chiou, W. L., Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm., 6, 539–546 (1978).

    Article  PubMed  CAS  Google Scholar 

  • Choi, B. C., Choi, J. S., and Han, H. K., Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats. Int. J. Pharm., 323, 81–85 (2006).

    Article  PubMed  CAS  Google Scholar 

  • Choi, H. J. and Choi, J. S., Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Arch. Pharm. Res., 28, 970–976 (2005).

    Article  PubMed  CAS  Google Scholar 

  • Choi, J. S., Piao, Y. J., and Kang, K. W., Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch. Pharm. Res., 34, 607–613 (2011).

    Article  PubMed  CAS  Google Scholar 

  • Choi, Y. H., Suh, J. H., Lee, J. H., Cho, I. H., and Lee, M. G., Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J. Pharm. Pharmcol., 62, 1084–1088 (2010).

    Article  CAS  Google Scholar 

  • Davies, B. and Morris, T., Physiological parameters in laboratory animals and humans. Pharm. Res., 10, 1093–1095 (1993).

    Article  PubMed  CAS  Google Scholar 

  • Fendl, K. C. and Zimniski, S. J., Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res., 52, 235–237 (1992).

    PubMed  CAS  Google Scholar 

  • Gibaldi, M. and Perrier, D., Pharmacokinetics. 2nd ed. Marcel-Dekker, New York, (1982).

    Google Scholar 

  • Hodek, P., Trefil, P., and Stiborová, M., Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1–21 (2002).

    Article  PubMed  CAS  Google Scholar 

  • Huggins, C., Grand, L. C., and Brillantes, F. P., Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature, 189, 204–207 (1961).

    Article  PubMed  CAS  Google Scholar 

  • Li, X., Yun, J. K., and Choi, J. S., Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm. Drug Dispos., 28, 151–156 (2007).

    Article  PubMed  Google Scholar 

  • Lwin, Z. and Leighl, N., Economic evaluation of docetaxel for breast cancer. Expert Opin. Pharmacother., 10, 283–290 (2009).

    Article  PubMed  CAS  Google Scholar 

  • Malingré, M. M., Richel, D. J., Beijnen, J. H., Rosing, H., Koopman, F. J., Ten Bokkel Huinink, W. W., Schot, M. E., and Schellens, J. H., Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol., 19, 1160–1166 (2001).

    PubMed  Google Scholar 

  • Marre, F., Sanderink, G. J., de Sousa, G., Gaillard, C., Martinet, M., and Rahmani, R., Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res., 56, 1296–1302 (1996).

    PubMed  CAS  Google Scholar 

  • Pathak, S. M. and Udupa, N., Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein substrate talinolol in combination with morin. Biopharm. Drug Dispos., 31, 202–214 (2010).

    PubMed  CAS  Google Scholar 

  • Piao, Y. J. and Choi, J. S., Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J. Pharm. Pharmacol., 60, 625–629 (2008).

    Article  PubMed  CAS  Google Scholar 

  • Russo, J. and Russo, I. H., Atlas and histologic classification of tumors of the rat mammary gland. J. Mammary Gland Biol. Neoplasia, 5, 187–200 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Sandström, M., Simonsen, L. E., Freijs, A., and Karlsson, M. O., The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemother. Pharmacol., 44, 469–474 (1999).

    Article  PubMed  Google Scholar 

  • Shin, S. C., Piao, Y. J., and Choi, J. S., Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. In Vivo, 22, 391–395 (2008).

    PubMed  CAS  Google Scholar 

  • Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H., Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs, 9, 1–17 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Suh, J. H., Kang, H. E., Yoon, I. S., Yang, S. H., Kim, S. H., Lee, H. J., Shim, C. K., and Lee, M. G., Cysteine effects on the pharmacokinetics of etoposide in protein-calorie malnutrition rats: increased gastrointestinal absorption by cysteine. Xenobiotica, 41, 885–894 (2011).

    Article  PubMed  CAS  Google Scholar 

  • Thummel, K. E., Gut instincts: CYP3A4 and intestinal drug metabolism. J. Clin. Invest., 117, 3173–3176 (2007).

    Article  PubMed  CAS  Google Scholar 

  • Vaclavikova, R., Soucek, P., Svobodova, L., Anzenbacher, P., Simek, P., Guengerich, F. P., and Gut, I., Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab. Dispos., 32, 666–674 (2004).

    Article  PubMed  CAS  Google Scholar 

  • Yang, S. H., Suh, J. H., and Lee, M. G., Pharmacokinetic interaction between tamoxifen and ondansetron in rats: non-competitive (hepatic) and competitive (intestinal) inhibition of tamoxifen metabolism by ondansetron via CYP2D subfamily and 3A1/2. Cancer Chemother. Pharmacol., 65, 407–418 (2010).

    Article  PubMed  CAS  Google Scholar 

  • Zhang, S. and Morris, M. E., Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 304, 1258–1267 (2003).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine, Dankook University, Cheonan, 330-714, Korea

    Si H. Yang

  2. College of Pharmacy, Kyunghee University, Seoul, 130-701, Korea

    Joo H. Lee

  3. Research Laboratory, Dong-A Pharmaceutical Company, Ltd., Yongin, 446-905, Korea

    Dae Y. Lee

  4. The Catholic University of Korea, Bucheon, 420-743, Korea

    Myung G. Lee

  5. Cranbrook High School, Bloomfield Hills, MI, 48304, USA

    Koon C. Lyuk

  6. College of Dentistry and Research Institute of Oral Science, Gangneung-Wonju National University, Gangneung, 210-702, Korea

    So H. Kim

Authors
  1. Si H. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joo H. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dae Y. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Myung G. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koon C. Lyuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. So H. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to So H. Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, S.H., Lee, J.H., Lee, D.Y. et al. Effects of morin on the pharmacokinetics of docetaxel in rats with 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. Arch. Pharm. Res. 34, 1729–1734 (2011). https://doi.org/10.1007/s12272-011-1017-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-011-1017-z

Key words

Search

Navigation